MAPT and Alzheimer disease: None of the MCI had a typical AD CSF biomarker pattern, although one subject presented reduced levels of CSF Aß42 with normal CSF tau and phosphor-tau levels (amyloidosis alone; data regarding AD CSF biomarkers and APOE genotype is shown in Table 1).